Mucormycosis in 2023: an update on pathogenesis and management

By sjmartinez • October 9, 2023

Alqarihi A, Kontoyiannis DP, Ibrahim AS. Mucormycosis in 2023: an update on pathogenesis and management. Front Cell Infect Microbiol. 2023 Sep 21;13:1254919. doi: 10.3389/fcimb.2023.1254919. PMID: 37808914; PMCID: PMC10552646.

Tags: COVID-19-associated mucormycosis, DKA, Harbor UCLA, immunosuppression, Infectious Diseases, invasive fungal infections, Mucorales, mucormycosis, pathogenicity, Publications, Rhizopus

FXYD2 marks and regulates maturity of (beta) cells via ion channel-mediated signal transduction

Tacto C, Tahbaz M, Salib A, Wang S, Cayabyab F, Choi J, Kim K, Hamba Y, Perez H, Gershon PD, Damoiseaux R, Oh TG, Yoshihara[...]

Comparative assessment of CAC and SIS plaque burden categories via AI-guided quantitative CT analysis

Iskander B, Ichikawa K, Punnanithinont N, Kambalapalli S, Kinninger A, Krishnan S, Lakshmanan S, Roy S, Budoff MJ. Comparative assessment of CAC and SIS plaque[...]

Reply: Keto CTA Study

Soto-Mota A, Norwitz NG, Manubolu VS, Kinninger A, Wood TR, Earls J, Feldman D, Budoff M. Reply: Keto CTA Study. JACC Adv. 2025 May 7;4(7):101862.[...]